Oakland Southfield Physicians

OSP News

FDA Approves Higher Dose of Ozempic

Posted: 03/31/2022

The FDA has approved a 2 mg dose of Ozempic (semaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) analog to improve blood sugar in adults with type 2 diabetes. Ozempic is now available in three doses (0.5 mg, 1 mg, and 2 mg) to help people with type 2 diabetes reach their blood sugar goals.

The approval is based on the phase 3 SUSTAIN FORTE trial, which found the higher dose of Ozempic helped patients who needed additional glycemic control. In the trial, people with an average starting A1c of 8.9% treated with Ozempic 2 mg achieved a reduction in A1c of 2.1% at week 40 compared with 1.9% with Ozempic 1 mg.

In the previous phase 3 SUSTAIN trial, up to 73% of people with type 2 diabetes treated with the 1 mg dose lowered their blood sugar and reached the American Diabetes Association target of <7%.

With the higher dose, the most common adverse events were gastrointestinal. Gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%).

Click here for more information on this approval.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support